CYCC News & Events

The company said, "The Company is not aware of any material developments or changes to its operating or financial condition that precipitated the volume and price movements that occurred on July 15, 2025. There have been no material adverse changes to the company's operating results, its business, strategy, or prospects other than what has been disclosed publicly by the Company to date, including an amendment to the Exchange Agreement with FITTERS Diversified Berhad announced on July 7, 2025."

Cyclacel Pharmaceuticals has entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad. Pursuant to the Exchange Agreement, all of the ordinary shares of FITTERS' subsidiary, Fitters Sdn. Bhd., shall be exchanged for common stock, par value $0.001, of Cyclacel, and Fitters Sub shall be continuing as a wholly-owned subsidiary of Cyclacel. As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. The amendment provides that in addition to the Purchaser Stock, Cyclacel will pay $1,000,000 or a mutually agreed upon amount at closing, to FITTERS as consideration under the Exchange Agreement. Additionally, the parties agreed to extend the Final Date to September 30, 2025. The Transaction is subject to approval from Cyclacel stockholders and FITTERS. The Exchange Agreement has been unanimously approved by the Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub.

Cyclacel Pharmaceuticals highlighted a publication from independent investigators titled, "DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma," published online in the journal Gut, a leading, peer-reviewed medical journal focused on gastroenterology and hepatology. The authors of the study described in the publication reported that DNAJ-PKAc, a fusion oncoprotein known to drive FLC progression, makes the cancer sensitive to treatment with plogosertib. The researchers found that PLK1 is essential for FLC cells making them highly sensitive to loss of PLK1. A direct interaction was found between DNAJ-PKAc fusions present in the centrosome and PLK1, thus promoting mitotic progression. Pharmacologic inhibitors of PLK1, such as plogosertib, significantly reduced FLC growth but spared normal liver cells in patient-derived in vitro and in vivo xenograft models and an orthotopic model of FLC. The article suggests that plogosertib should be further evaluated as a potential treatment for FLC in further preclinical and clinical studies.

Cyclacel Pharmaceuticals announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol "CYCC". The new CUSIP number for the shares of common stock following the reverse stock split is 23254L876.